Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, treatment with DPCP alone was more effective for hair regrowth and presented fewer side effects in chronic extensive alopecia areata compared to combination therapy with DPCP and anthralin.

Baricitinib stops hair loss and promotes regrowth in alopecia areata.

This review reports that extracts from the plant Eclipta alba, traditionally used in herbal medicine, may promote hair growth by inhibiting TGF-β1 expression and functioning as a 5α-reductase inhibitor, potentially benefiting androgenic alopecia treatment.

This study found that Paeonia lactiflora and Poria cocos extracts promoted hair regrowth in a mouse model of androgenetic alopecia, with similar effects observed to normal controls.

This study found that inhibiting arachidonate 12-lipoxygenase (ALOX12) may enhance hair cuticle maturation by increasing S100A3 protein citrullination and promoting cuticular differentiation in isolated human hair follicles.

This entry contains no research abstract, so no scientific findings or conclusions are reported.

This study found that a high sesquiterpene C. aeruginosa extract significantly reduced axillary hair growth in women compared to placebo with no apparent adverse effects.

This study presents a hypothesis that the EDAR V370A allele was positively selected in East Asian populations due to the stable aquatic resources in Late Pleistocene northern China, which may have offset the allele's metabolic costs and provided a selective advantage.

This study investigates the potential link between atrial fibrillation and circulating aldosterone levels related to cardiac fibrosis in patients with hypertension.

This article discusses ongoing research efforts to develop natural anti-androgenetic alopecia treatments using bioactive compounds from medicinal plants but reports no new clinical results.

This review summarizes structural insights into androgen receptor dynamics, highlighting its flexibility in binding numerous partners, which may explain adaptive resistance mutations in cancer and loss of function in androgen insensitivity syndrome.

This review details how baricitinib successfully demonstrated significant hair regrowth in clinical trials for severe alopecia areata, now leading to its approval as the first systemic therapy for the condition, while also highlighting the importance of assessing individual risk factors for adverse events.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

This study concluded that ALRV5XR treatment significantly increased terminal hair density in both men and women with androgenetic alopecia and telogen effluvium, with more pronounced effects in women.

This study shows that IKZF1 and the protein IKAROS may play a role in the development of alopecia areata, based on findings from both mouse models and human scalp tissues.

In this case report, the authors describe a child with treatment-resistant alopecia areata who successfully responded to leflunomide and anthralin, proposing this combination as a potentially cost-effective alternative for managing recalcitrant cases by possibly inhibiting the JAK/STAT pathway.

This article discusses alopecia areata incognito, highlighting its diffuse hair loss pattern and favorable response to steroid treatment, but it reports no new clinical data.

This study found that full-length Agouti protein modulates melanocortin receptor signaling through a dual mechanism involving competitive antagonism and receptor down-regulation, whereas the carboxyl-terminal fragment acts solely as a competitive antagonist.

This review discusses the role of acyl-CoA binding protein (ACBP) in the epidermal barrier, noting that its disruption in mice is linked to skin and fur abnormalities; it reports no new clinical results.

Baricitinib reduces inflammation and mitochondrial damage in skin cells.

This study revealed that tofacitinib may inhibit CD8⁺ T cell infiltration in alopecia areata by modulating the linoleic acid metabolism-Mg²⁺ pathway, providing new insights for potential treatments and diagnosis.

This review suggests that annurca apple extract, rich in polyphenols, may be a promising alternative for treating baldness, though further research is needed to clearly assess its effectiveness compared to existing treatments.

This study suggests that the "spade sign" is a highly specific histopathologic feature of acne keloidalis, although its absence does not rule out the condition.

This study found that after 15 months of treatment with ritlecitinib, patients with alopecia areata and less than 95% initial hair loss experienced significant hair regrowth, though those with more extensive hair loss showed more variable improvement.

This study demonstrated that the Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata cases with high sensitivity and specificity in a dermatology clinic setting.

This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.

This study found that the optimized AR antagonist compound 39 showed potent hair growth activity with improved safety in mice, suggesting potential for better topical treatments for androgenetic alopecia.